62 results
10-Q
2013 Q2
TXMD
TherapeuticsMD Inc
Quarterly report
>falsefalse Supplier Concentration Risk us …
7 Aug 13
12:00am
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
13 Aug 18
TherapeuticsMDAnnounces FDA Approval of ANNOVERA ™(Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
6:01am
women aged 15 to 44.v
TherapeuticsMD intends to leverage the Population Council’s existing relationships with the supplier of segesterone acetate
8-K
EX-2.1
jcvjsyq
10 Mar 22
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
7:15am
DEF 14C
eeb ycqrlxzif
12 Sep 11
Information statement
12:00am
8-K
EX-10.2
m8eapvn9 atev76
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
8-K
EX-10
saai6q6e 8me
11 Oct 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
njb bls2vi98la
15 Mar 13
TherapeuticsMD Announces Pricing of Public Offering of Common Stock
12:00am
8-K
EX-1.1
n8icx6ng88 6i81
4 Aug 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
x4wfef en
29 Oct 19
Entry into a Material Definitive Agreement
8:52am
8-K
EX-1.1
z7x5dyvaxv9w4e97ej
16 Feb 21
Entry into a Material Definitive Agreement
8:35am